Invex Therapeutics Ltd
Invex Therapeutics Ltd is an Australia-based biopharmaceutical company.
The business
Invex Therapeutics Ltd is an Australia-based biopharmaceutical company. The Company is focused on the repurposing of an already-approved drug, Exenatide, for the efficacious treatment of neurological conditions derived from or involving raised intracranial pressure (ICP). In addition, the Company has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. The principal activity of the Company is the development of Exenatide, including generating new pre-clinical data in Alzheimer’s Disease (AD) under a collaboration with Tessara Therapeutics. The Company has trademarked its repurposed Exenatide as Presendin. The Company is focused on managing the close out of the Phase III Idiopathic Intracranial Hypertension (IIH) EVOLVE clinical trial and explore new potential applications for Exenatide in TBI and other neurological disorders with raised ICP, consistent with its patents.
Small Caps Research
No research on Invex Therapeutics Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise IXC based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Invex Therapeutics receives tax rebate for neurological drug research
Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has announced it has received about £100,000 (A$186,000) in a research and development tax rebate from the UK government for the 2021 financial year. The rebate relates to research and development activities conducted by its subsidiary Invex UK, including research undertaken in the lead-up to a planned phase three […]
Invex Therapeutics opens first US clinical site for Presendin trials
Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has announced the opening of its first US-based clinical site at the Eye Wellness Centre in Texas. The centre is run by respected neuro-ophthalmologist Dr Rose Tang and will be integral to trials of the company’s lead candidate Presendin (sustained-release Exenatide) for neurological conditions relating to raised intracranial […]
Invex Therapeutics gets EU approval to develop Presendin for adolescents with idiopathic intracranial hypertension
A paediatric investigation plan (PIP) submitted by Invex Therapeutics (ASX: IXC) for the development of lead drug Presendin in the treatment of idiopathic intracranial hypertension (IIH) in adolescents has been accepted by the European Medicines Agency. The approval will allow Invex to develop Presendin for IIH patients who are under 18 years of age and […]
Invex Therapeutics to begin recruiting IIH patients in NZ for clinical trial following regulatory approvals
Invex Therapeutics (ASX: IXC) has secured approval to expand its Evolve phase III clinical trial into New Zealand, where it will evaluate its drug Presendin in patients with idiopathic intracranial hypertension (IIH). The New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) granted approval for the trial along with Invex getting the green light from […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.